Exemestane

Correction: Methotrexate-lactoferrin targeted exemestane cubosomes for synergistic breast cancer therapy.

Journal: Frontiers in chemistry

Published: May 17, 2026

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 16, 2026

Effects of dietary exemestane administration on reproductive performance, hepatic function, and lipid metabolism in Japanese quail.

Journal: Poultry science

Published: April 09, 2026

Recurrent Radiation-Induced Angiosarcoma of the Breast Without Distant Metastasis: A Case Report.

Journal: Cureus

Published: April 09, 2026

Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study.

Journal: ESMO real world data and digital oncology

Published: April 03, 2026

Outcomes of Anastrozole, Letrozole, and Exemestane in Patients With Postmenopausal Breast Cancer.

Journal: JAMA network open

Published: February 03, 2026

Planning and Developing a Symptom Diary Intervention for Breast Cancer Survivors With Concerns About Medication Brands (ENABLE Study): User-Centered Design Approach.

Journal: JMIR cancer

Published: January 11, 2026

Imlunestrant (Inluriyo) for advanced breast cancer.

Journal: The Medical letter on drugs and therapeutics

Published: January 08, 2026

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial.

Journal: ESMO open

Published: January 05, 2026

Comparison Between Alpelisib Plus Endocrine Therapy and Everolimus Plus Endocrine Therapy After CDK4/6 Inhibitors Progression in Patients with PIK3CA-Mutant Metastatic Breast Cancer: A Single-Center Retrospective Study.

Journal: Cancers

Published: December 29, 2025

Sequential CDK4/6 inhibition in bone-only metastatic HR+/HER2- breast cancer: a case of prolonged disease control with abemaciclib after clinical progression on palbociclib-based therapy.

Correction: Methotrexate-lactoferrin targeted exemestane cubosomes for synergistic breast cancer therapy.

Correction: Methotrexate-lactoferrin targeted exemestane cubosomes for synergistic breast cancer therapy.

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

Effects of dietary exemestane administration on reproductive performance, hepatic function, and lipid metabolism in Japanese quail.

Effects of dietary exemestane administration on reproductive performance, hepatic function, and lipid metabolism in Japanese quail.

Recurrent Radiation-Induced Angiosarcoma of the Breast Without Distant Metastasis: A Case Report.

Recurrent Radiation-Induced Angiosarcoma of the Breast Without Distant Metastasis: A Case Report.

Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study.

Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study.

Outcomes of Anastrozole, Letrozole, and Exemestane in Patients With Postmenopausal Breast Cancer.

Outcomes of Anastrozole, Letrozole, and Exemestane in Patients With Postmenopausal Breast Cancer.

Planning and Developing a Symptom Diary Intervention for Breast Cancer Survivors With Concerns About Medication Brands (ENABLE Study): User-Centered Design Approach.

Planning and Developing a Symptom Diary Intervention for Breast Cancer Survivors With Concerns About Medication Brands (ENABLE Study): User-Centered Design Approach.

Imlunestrant (Inluriyo) for advanced breast cancer.

Imlunestrant (Inluriyo) for advanced breast cancer.

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial.

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial.

Comparison Between Alpelisib Plus Endocrine Therapy and Everolimus Plus Endocrine Therapy After CDK4/6 Inhibitors Progression in Patients with PIK3CA-Mutant Metastatic Breast Cancer: A Single-Center Retrospective Study.

Comparison Between Alpelisib Plus Endocrine Therapy and Everolimus Plus Endocrine Therapy After CDK4/6 Inhibitors Progression in Patients with PIK3CA-Mutant Metastatic Breast Cancer: A Single-Center Retrospective Study.

Sequential CDK4/6 inhibition in bone-only metastatic HR+/HER2- breast cancer: a case of prolonged disease control with abemaciclib after clinical progression on palbociclib-based therapy.

Sequential CDK4/6 inhibition in bone-only metastatic HR+/HER2- breast cancer: a case of prolonged disease control with abemaciclib after clinical progression on palbociclib-based therapy.

Lichenoid drug eruption induced by letrozole: a case report.

Lichenoid drug eruption induced by letrozole: a case report.